文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

CD19特异性CAR T细胞疗法在伴中枢神经系统白血病的B细胞急性淋巴细胞白血病患者中的疗效与安全性

Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
PubMed 文献 · Blood · 2022-01-01

本研究纳入48例伴中枢神经系统白血病(CNSL)的复发/难治性B细胞急性淋巴细胞白血病(B-ALL)患者,评估CD19特异性CAR T细胞疗法的疗效与安全性。骨髓病总缓解率为87.5%(95%CI 75.3-94.1),CNSL缓解率为85.4%(95%CI 72.8-92.8)。中位随访11.5个月,中位无事件生存8.7个月,中位总生存16.0个月;12个月时骨髓与CNS复发累积发生率分别为31.1%和11.3%(P=.040)。

要点

  • CD19 CAR T细胞疗法在骨髓病和CNSL中均诱导高缓解率,骨髓总缓解率87.5%,CNSL缓解率85.4%。
  • 12个月时骨髓复发累积发生率为31.1%,CNS复发累积发生率为11.3%,CNSL缓解持续时间长于骨髓病。
  • 9例(18.8%)发生≥3级细胞因子释放综合征,11例(22.9%)发生3-4级神经毒性事件,与输注前CNS疾病负荷较高相关。

核心结论

  • CD19特异性CAR T细胞疗法可在骨髓病和CNS病中诱导相似的高缓解率,CNSL缓解持续时间长于骨髓病。
  • 该疗法可能为既往被排除的CNSL患者提供潜在治疗选择,神经毒性可控。

研究设计与样本

  • 研究纳入48例伴CNSL的复发/难治性B-ALL患者,评估CD19特异性CAR T细胞疗法的疗效与安全性。
  • 临床试验注册号:NCT02782351和ChiCTR-OPN-16008526。

主要发现

  • 骨髓病总缓解率为87.5%(95%CI 75.3-94.1),CNSL缓解率为85.4%(95%CI 72.8-92.8)。
  • 中位随访11.5个月(范围1.3-33.3),中位无事件生存8.7个月(95%CI 3.7-18.8),中位总生存16.0个月(95%CI 13.5-20.1)。
  • 12个月时骨髓病复发累积发生率为31.1%,CNS病复发累积发生率为11.3%(P=.040)。
  • 9例(18.8%)发生≥3级细胞因子释放综合征。
  • 11例(22.9%)发生3-4级神经毒性事件,与输注前CNS疾病负荷较高相关,在强化管理下得到有效控制。

临床怎么用

  • 作者认为,CD19 CAR T细胞疗法可能为既往被排除的CNSL患者提供潜在治疗选择,神经毒性可控。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Few studies have described chimeric antigen receptor (CAR) T-cell therapy for patients with B-cell acute lymphoblastic leukemia (B-ALL) with central nervous system leukemia (CNSL) because of concerns regarding poor response and treatment-related neurotoxicity. Our study included 48 patients with relapsed/refractory B-ALL with CNSL to evaluate the efficacy and safety of CD19-specific CAR T cell-based therapy. The infusion resulted in an overall response rate of 87.5% (95% confidence interval [CI], 75.3-94.1) in bone marrow (BM) disease and remission rate of 85.4% (95% CI, 72.8-92.8) in CNSL. With a median follow-up of 11.5 months (range, 1.3-33.3), the median event-free survival was 8.7 months (95% CI, 3.7-18.8), and the median overall survival was 16.0 months (95% CI, 13.5-20.1). The cumulative incidences of relapse in BM and CNS diseases were 31.1% and 11.3%, respectively, at 12 months (P = .040). The treatment was generally well tolerated, with 9 patients (18.8%) experiencing grade ≥3 cytokine release syndrome. Grade 3 to 4 neurotoxic events, which developed in 11 patients (22.9%), were associated with a higher preinfusion disease burden in CNS and were effectively controlled under intensive management. Our results suggest that CD19-specific CAR T cell-based therapy can induce similar high response rates in both BM and CNS diseases. The duration of remission in CNSL was longer than that in BM disease. CD19 CAR T-cell therapy may provide a potential treatment option for previously excluded patients with CNSL, with manageable neurotoxicity. The clinical trials were registered at www.clinicaltrials.gov as #NCT02782351 and www.chictr.org.cn as #ChiCTR-OPN-16008526.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Qi Y, Zhao M, Hu Y, et al. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood. 2022. PMID: 35338773. doi:10.1182/blood.2021013733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。